Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
Part of paid clinical trials in Austin, Texas.
- Sponsor
- Boston Scientific Corporation
- Study ID
- NCT07575269
- Status
- Recruiting
Conditions
- Paroxysmal Atrial Fibrillation (PAF)
- Persistent Atrial Fibrillation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- FARAFLEX Mapping and Pulsed Field Ablation (PFA) System — DEVICECatheter used to perform cardiac electrophysiological mapping and deliver cardiac tissue ablation therapy for the treatment of Atrial Fibrillation.
Study Details
The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is: Is the FARAFLEX Mapping and PFA System a safe and effective treatment for patients? Participants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.
Key Dates
- Start date
- Jun 12, 2026
- Status verified
- May 2026
- Primary completion
- Jun 12, 2028
- Completion
- Jan 1, 2030
Study Design
- Enrollment
- 571 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: FARAFLEX Mapping and Pulsed Field Ablation (PFA) SystemParticipants undergo a catheter procedure using the FARAFLEX Mapping and Pulsed Field Ablation (PFA) System to treat atrial fibrillation. The catheter is used to map the heart's electrical signals and deliver pulsed field ablation therapy.
Primary Outcome Measure
Proportion of Treatment Subjects and Attempt Subjects with device- or procedure-related defined Composite Serious Adverse Events, assessed through Day 60 following the index procedure. [ Time Frame: After the index procedure, rescheduled index procedure, or first re-ablation performed with the FARAFLEX (Day 0) through Day 60 ]
Central Contacts
- Madalyn MacKinnon860-992-2724
- Sara Veraghtert
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Texas Cardiac Arrhythmia Research | Austin | Texas | 78705 | Deb Cardinal Andrea Natale, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Austin, TX
Related Studies
- Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial FibrillationRecruiting · Heart Rhythm Clinical and Research Solutions, LLC · Birmingham, Alabama
- ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation PatientsRecruiting · Vivek Reddy · Jonesboro, Arkansas
- Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation SystemRecruiting · Boston Scientific Corporation · Mobile, Alabama
- Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)Recruiting · Medtronic Cardiac Ablation Solutions · Birmingham, Alabama